Link Technologies Inks Licensing Deal with RiboTask | GenomeWeb

NEW YORK (GenomeWeb News) – Reagents maker Link Technologies said today that it will sell RiboTask's nucleic acid monomers, under a new license agreement.

Link, a Scottish company, will make and commercialize RiboTask's unlocked-nucleic acid (UNA) monomer phosphoramadite reagents, which are used to enable fine-tuning of oligonucleotide stability in siRNA gene silencing and other applications.

Patents for the therapeutic use of UNA oligonucleotides are held by MDRNA, according to Link.

Financial terms of the agreement were not released.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.